{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:56:57Z","timestamp":1773417417885,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"crossref","award":["LIO 601741 and LIO 697051"],"award-info":[{"award-number":["LIO 601741 and LIO 697051"]}],"id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Women are advised to primarily use non-oral contraceptive alternatives after Roux-en-Y gastric bypass since it is not known if the surgery affects the pharmacokinetics of oral contraceptives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a multi-center, open label, phase 2 pharmacokinetic study performed at the University Hospital of Link\u00f6ping and the Clinical Trials Center, Department of Obstetrics and Gynecology, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. Fifteen women aged 18\u201340\u00a0years who had previously undergone Roux-en-Y gastric bypass surgery and reached a BMI\u2009&lt;\u200930 were included. Fifteen BMI-matched women with no previous history of Roux-en-Y gastric bypass surgery served as a control group. After administration of a single dose of a combined oral contraceptive containing 0.03\u00a0mg ethinylestradiol\/0.15\u00a0mg levonorgestrel, serum levonorgestrel concentrations were determined during a 24-h period using ultra performance liquid chromatography\/tandem mass spectrometry. The area under the plasma concentration time curve of levonorgestrel (AUC<jats:sub>0\u201324h<\/jats:sub>) was the main outcome measure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant differences in the studied pharmacokinetic parameters, AUC<jats:sub>0\u201324h<\/jats:sub>, total AUC, peak serum concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>), time to peak serum concentrations (<jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>), apparent oral clearances of levonorgestrel (CL<jats:sub>oral<\/jats:sub>), or terminal half-lives (<jats:italic>t<\/jats:italic>\u00bd) between the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is to our knowledge the first study to evaluate the pharmacokinetics of oral levonorgestrel in women with a BMI\u2009&lt;\u200930 at least 1\u00a0year after RYGB compared with a BMI-matched group of women. We could not find any significant pharmacokinetic differences between the groups, suggesting that oral levonorgestrel may be used in non-obese women after Roux-en-Y gastric bypass once a stable body weight has been reached.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Number<\/jats:title><jats:p>EudraCT 2014\u2013004677-17.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11695-020-04447-x","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:02:42Z","timestamp":1581044562000},"page":"2217-2224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of Oral Levonorgestrel in Women After Roux-en-Y Gastric Bypass Surgery and in BMI-Matched Controls"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-1173","authenticated-orcid":false,"given":"Charlotte","family":"Ginstman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Kopp Kallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Fagerberg-Silwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"\u00c4rlemalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylva","family":"B\u00f6ttiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Brynhildsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"issue":"8","key":"4447_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s11695-007-9389-3","volume":"18","author":"JH Beard","year":"2008","unstructured":"Beard JH, Bell RL, Duffy AJ. Reproductive considerations and pregnancy after bariatric surgery: current evidence and recommendations. Obes Surg. 2008;18(8):1023\u20137.","journal-title":"Obes Surg"},{"issue":"6","key":"4447_CR2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1097\/AOG.0b013e3181ac0544","volume":"113","author":"American College of O, and, Gynecologists","year":"2009","unstructured":"American College of O, and, Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol. 2009;113(6):1405\u201313.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"4447_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ajog.2018.02.003","volume":"218","author":"W Kwong","year":"2018","unstructured":"Kwong W, Tomlinson G, Feig DS. Maternal and neonatal outcomes after bariatric surgery; a systematic review and meta-analysis: do the benefits outweigh the risks? Am J Obstet Gynecol. 2018;218(6):573\u201380.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"4447_CR4","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1007\/s11695-018-3450-2","volume":"28","author":"L Angrisani","year":"2018","unstructured":"Angrisani L, Santonicola A, Iovino P, et al. IFSO Worldwide Survey 2016: primary, endoluminal, and revisional procedures. Obes Surg. 2018;28(12):3783\u201394.","journal-title":"Obes Surg"},{"issue":"10","key":"4447_CR5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s11695-015-1657-z","volume":"25","author":"L Angrisani","year":"2015","unstructured":"Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822\u201332.","journal-title":"Obes Surg"},{"key":"4447_CR6","unstructured":"SOReg. Annual report SOReg 2017. Scandinavian Obesity Surgery Registry 2017. (In Swedish). 2018. Available at: https:\/\/www.ucr.uu.se\/soreg\/component\/edocman\/arsrapport-2017-del-1. Accessed April 21, 2019."},{"issue":"23","key":"4447_CR7","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2146\/ajhp100630","volume":"68","author":"A Smith","year":"2011","unstructured":"Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm. 2011;68(23):2241\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"4447_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.soard.2010.12.003","volume":"8","author":"JL Roerig","year":"2012","unstructured":"Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8(1):62\u20136.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"4447_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FTD.0000000000000146","volume":"37","author":"MA Marzinke","year":"2015","unstructured":"Marzinke MA, Petrides AK, Steele K, et al. Decreased escitalopram concentrations post-Roux-en-Y gastric bypass surgery. Ther Drug Monit. 2015;37(3):408\u201312.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"4447_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JCP.0b013e3182905ffb","volume":"33","author":"JL Roerig","year":"2013","unstructured":"Roerig JL, Steffen KJ, Zimmerman C, et al. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol. 2013;33(4):479\u201384.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"4447_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40262-014-0163-0","volume":"53","author":"C Lloret-Linares","year":"2014","unstructured":"Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014;53(10):919\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"4447_CR12","doi-asserted-by":"crossref","unstructured":"Krieger CA, Cunningham JL, Reid JM, Langman LJ, Grothe KB, Clark MM, et al. Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery. Pharmacotherapy. 2017.","DOI":"10.1002\/phar.2022"},{"issue":"2","key":"4447_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/SLA.0b013e31827a0e82","volume":"258","author":"S Tandra","year":"2013","unstructured":"Tandra S, Chalasani N, Jones DR, et al. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262\u20139.","journal-title":"Ann Surg"},{"issue":"5","key":"4447_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/bcp.12666","volume":"80","author":"I Gesquiere","year":"2015","unstructured":"Gesquiere I, Darwich AS, Van der Schueren B, et al. Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations. Br J Clin Pharmacol. 2015;80(5):1021\u201330.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4447_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0889-8553(21)00311-3","volume":"16","author":"A Victor","year":"1987","unstructured":"Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin N Am. 1987;16(3):483\u201391.","journal-title":"Gastroenterol Clin N Am"},{"issue":"1","key":"4447_CR16","first-page":"91","volume":"6","author":"AN Andersen","year":"1982","unstructured":"Andersen AN, Lebech PE, Sorensen TI, et al. Sex hormone levels and intestinal absorption of estradiol and D-norgestrel in women following bypass surgery for morbid obesity. Int J Obes. 1982;6(1):91\u20136.","journal-title":"Int J Obes"},{"key":"4447_CR17","doi-asserted-by":"crossref","unstructured":"Ginstman C, Frisk J, Carlsson B, et al. Plasma concentrations of etonogestrel in obese women using oral desogestrel before and after Roux-en-Y gastric bypass surgery (RYGB): a pharmacokinetic study. BJOG. 2018;","DOI":"10.1111\/1471-0528.15511"},{"issue":"3","key":"4447_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1055\/s-0037-1613379","volume":"89","author":"M Abdollahi","year":"2003","unstructured":"Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89(3):493\u20138.","journal-title":"Thromb Haemost"},{"issue":"8","key":"4447_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jama.1997.03540320044033","volume":"277","author":"SZ Goldhaber","year":"1997","unstructured":"Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277(8):642\u20135.","journal-title":"JAMA."},{"issue":"2","key":"4447_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","volume":"139","author":"ER Pomp","year":"2007","unstructured":"Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139(2):289\u201396.","journal-title":"Br J Haematol"},{"key":"4447_CR21","unstructured":"L\u00e4kemedelsverket. Antikonception-behandlingsrekommendation. Information fr\u00e5n l\u00e4kemedelsverket. 25(2)(2014), pp.14\u201328. In Swedish."},{"issue":"1","key":"4447_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/13625187.2014.960561","volume":"20","author":"GS Merki-Feld","year":"2015","unstructured":"Merki-Feld GS, Skouby S, Serfaty D, et al. European society of contraception statement on contraception in obese women. Eur J contracept Reprod Health Care. 2015;20(1):19\u201328.","journal-title":"Eur J contracept Reprod Health Care"},{"issue":"Suppl 1","key":"4447_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/oby.20461","volume":"21","author":"JI Mechanick","year":"2013","unstructured":"Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity. 2013;21(Suppl 1):S1\u201327.","journal-title":"Obesity."},{"key":"4447_CR24","unstructured":"RCOG. The Role of Bariatric Surgery in Improving Reproductive Health. Scientific Impact Paper 2015;No.17(October 2015)."},{"issue":"4","key":"4447_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FTD.0b013e3182241799","volume":"33","author":"I Saeves","year":"2011","unstructured":"Saeves I, Vethe NT, Bergan S. Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects. Ther Drug Monit. 2011;33(4):402\u201310.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"4447_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0010-7824(96)00183-7","volume":"54","author":"J Spona","year":"1996","unstructured":"Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception. 1996;54(5):299\u2013304.","journal-title":"Contraception."},{"issue":"2","key":"4447_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/ejc.7.2.79.90","volume":"7","author":"J Endrikat","year":"2002","unstructured":"Endrikat J, Blode H, Gerlinger C, et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care. 2002;7(2):79\u201390.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"4447_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6904-12-8","volume":"12","author":"PA Kothare","year":"2012","unstructured":"Kothare PA, Seger ME, Northrup J, et al. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012;12:8.","journal-title":"BMC Clin Pharmacol"},{"issue":"11","key":"4447_CR29","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/phar.2022","volume":"37","author":"CA Krieger","year":"2017","unstructured":"Krieger CA, Cunningham JL, Reid JM, et al. Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery. Pharmacotherapy. 2017;37(11):1374\u201382.","journal-title":"Pharmacotherapy."},{"issue":"12","key":"4447_CR30","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1089\/jwh.2010.2704","volume":"20","author":"SK Mody","year":"2011","unstructured":"Mody SK, Hacker MR, Dodge LE, et al. Contraceptive counseling for women who undergo bariatric surgery. J Women's Health. 2011;20(12):1785\u20138.","journal-title":"J Women's Health"},{"issue":"11","key":"4447_CR31","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1007\/s11695-015-1641-7","volume":"25","author":"C Ginstman","year":"2015","unstructured":"Ginstman C, Frisk J, Ottosson J, et al. Contraceptive use before and after gastric bypass: a questionnaire study. Obes Surg. 2015;25(11):2066\u201370.","journal-title":"Obes Surg"},{"key":"4447_CR32","volume-title":"Clinical gynecologic endocrinology and infertility","author":"MA Fritz","year":"2011","unstructured":"Fritz MA, Speroff L. Oral contraception. In: Fritz MA, Speroff L, editors. Clinical gynecologic endocrinology and infertility. Philadelphia: Lippincott Williams & Wikins; 2011."},{"issue":"2","key":"4447_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0010-7824(85)90034-4","volume":"31","author":"LO Nilsson","year":"1985","unstructured":"Nilsson LO, Victor A, Kral JG, et al. Absorption of an oral contraceptive gestagen in ulcerative colitis before and after proctocolectomy and construction of a continent ileostomy. Contraception. 1985;31(2):195\u2013204.","journal-title":"Contraception"},{"issue":"1","key":"4447_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0010-7824(86)90032-6","volume":"33","author":"SF Grimmer","year":"1986","unstructured":"Grimmer SF, Back DJ, Orme ML, et al. The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception. 1986;33(1):51\u20139.","journal-title":"Contraception"},{"issue":"3","key":"4447_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.1989.tb05368.x","volume":"27","author":"S Madden","year":"1989","unstructured":"Madden S, Back DJ, Martin CA, et al. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol. 1989;27(3):295\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4447_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/AOG.0000000000002323","volume":"130","author":"MN Menke","year":"2017","unstructured":"Menke MN, King WC, White GE, et al. Contraception and conception after bariatric surgery. Obstet Gynecol. 2017;130(5):979\u201387.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"4447_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/0091270003256065","volume":"43","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43(9):943\u201367.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4447_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0010-7824(01)00226-8","volume":"64","author":"I Sivin","year":"2001","unstructured":"Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001;64(1):43\u20139.","journal-title":"Contraception."},{"issue":"4","key":"4447_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.contraception.2016.12.007","volume":"95","author":"CN Basaraba","year":"2017","unstructured":"Basaraba CN, Westhoff CL, Pike MC, et al. Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception. 2017;95(4):398\u2013404.","journal-title":"Contraception."},{"issue":"5","key":"4447_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0010-7824(92)90149-N","volume":"46","author":"W Kuhnz","year":"1992","unstructured":"Kuhnz W, al-Yacoub G, Fuhrmeister A. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Contraception. 1992;46(5):455\u201369.","journal-title":"Contraception."},{"issue":"6","key":"4447_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","volume":"81","author":"CL Westhoff","year":"2010","unstructured":"Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010;81(6):474\u201380.","journal-title":"Contraception."},{"issue":"2","key":"4447_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0010-7824(96)00136-9","volume":"54","author":"K Fotherby","year":"1996","unstructured":"Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. 1996;54(2):59\u201369.","journal-title":"Contraception."}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-020-04447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11695-020-04447-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-020-04447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T17:47:06Z","timestamp":1665769626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11695-020-04447-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4447"],"URL":"https:\/\/doi.org\/10.1007\/s11695-020-04447-x","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"7 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"HKK reports funding from Bayer as an investigator in clinic trials sponsored by Bayer as well as honorariums paid for lectures and participation on advisory boards. All other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed were in accordance with the Helsinki Declaration and good clinical practice. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The study was approved on 27 January 2016 by the Regional Ethical Review Board in Link\u00f6ping, Sweden (No. 2016\/22-31) and on 16 March 2016 by the Medical Products Agency (EudraCT 2014-004677-17).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The funder had no role at all in the process from study design to submission of the article for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}